89bio, Inc.
Clinical trials sponsored by 89bio, Inc., explained in plain language.
-
Breakthrough drug trial aims to reverse liver scarring in advanced disease
Disease control Recruiting nowThis study is testing whether an investigational drug called pegozafermin can reduce liver scarring in people with advanced MASH-related cirrhosis. Researchers will enroll 762 adults with confirmed liver scarring but without liver failure to receive either the drug or placebo for…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Apr 02, 2026 05:42 UTC
-
Major trial tests new drug to halt scarring in fatty liver disease
Disease control Recruiting nowThis study aims to see if a new drug called pegozafermin is safe and effective at treating MASH, a serious form of fatty liver disease that causes scarring. It will involve about 1,350 adults who have moderate liver scarring from MASH. Participants will receive either pegozafermi…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC